Tissues stiffen during aging and during the pathological progression of cancer, fibrosis, and cardiovascular disease. Extracellular matrix stiffness is emerging as a prominent mechanical cue that precedes disease and drives its progression by altering cellular behaviors. Targeting extracellular matrix mechanics, by preventing or reversing tissue stiffening or interrupting the cellular response, is a therapeutic approach with clinical potential. Potential pharmacological interventions to overcome extracellular matrix stiffening are emerging clinically. Therapeutic interventions that target tissue stiffening are discussed in the context of their limitations, preclinical drug development efforts, and clinical trials.
In HCS Pharma, We really believe that developing relevant cellular in vitro model close to the in vivo situation is a key point to find new therapeutic drugs in neurodegenerative disease, cardiometabolic disease or in oncology. To implement cellular screening models close to in vivo situation, We use BIOMIMESYS® 3D system, an exclusive and innovative biofunctionalized natural scaffold. If you want to know more on this 3D scaffold system, follow this link or contact us!